Search - tctmd.com

Displaying 21 - 40 of 448

Sort: Relevancy | Date

Presentation TCT 2024

Can AI-Assisted Earlier AS Diagnosis Level the Disparities Playing Field?

Presenter: Pierre Elias

October 30, 2024

Presentation TCT 2024

Impact of Delays in Diagnosis and Treatment: Join the AHA TARGET AS Program!

Presenter: Brian Lindman

October 30, 2024

Presentation TCT 2024

Patient Perspectives and Shared Decision-Making in Younger Patients Requiring AS Therapy

Presenter: Megan Coylewright

October 30, 2024

Presentation TCT 2024

Surgical Valve Selection in Younger Patients with AS: Mechanical, Bioprosthetic, or Ross?

Presenter: Katherine Harrington

October 30, 2024

Presentation TCT 2024

The Emerging Use of TAVR in Younger Patients: Updates and Evidence Gaps

Presenter: Harold Dauerman

October 30, 2024

Presentation TCT 2024

Transcatheter vs. Surgical Aortic Valve Replacement in Women: A Pooled Analysis of the RHEIA and PARTNER 3 Trials

Presenter: Didier Tchetche

October 29, 2024

News Conference News TCT 2024

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

L.A. McKeown

October 28, 2024

News Opinion Editor's Corner TCT 2024

What’s Going to Be Big at TCT 2024?

Michael O'Riordan

October 17, 2024

News Industry News

Pi-Cardia Receives FDA Market Clearance for ShortCut™

October 01, 2024

News Conference News ESC 2024

Balloon-Expandable TAVI Superior to SAVR in Women at 1 Year: RHEIA

Caitlin E. Cox

September 04, 2024

News Features

Initial US Commercial TriClip Cases Offer Hope, but Reimbursement Still a Big Question

L.A. McKeown

August 09, 2024

News Daily News

Knowns and Unknowns in Subclinical Aortic Valve Thrombosis

Caitlin E. Cox

June 21, 2024

News Conference News NY Valves 2024

National Data Point to Soaring TAVI Rates in Patients Under 65

Michael O'Riordan

June 14, 2024

Presentation NY Valves 2024

UPDATES: Pre-emptive AVR Clinical Trials for Moderate and Severe AS

Presenter: Philippe Pibarot

June 07, 2024

Presentation NY Valves 2024

There Is Growing Evidence to Support Earlier AS Treatment: Guidelines and Clinical Practice Are Lagging Behind!

Presenter: Philippe Genereux

June 07, 2024

Presentation NY Valves 2024

Access Disparities Affecting Appropriate AS Therapy

Presenter: David A. Wood

June 07, 2024

Presentation NY Valves 2024

Impact of Delays in Diagnosis and Treatment: Introducing the TARGET AS Program

Presenter: Brian R. Lindman

June 07, 2024

Presentation NY Valves 2024

Thoughts on Therapy Sequencing in Younger Patients With AS and Long Life Expectancy

Presenter: Michael J. Reardon

June 07, 2024

Presentation NY Valves 2024

Patient Interview: Understanding the Impact of Patient Preferences and Other Determinants of VHD Therapy Choices

Presenter: Robert L. Smith, Megan Coylewright

June 07, 2024

Presentation NY Valves 2024

Partner Valves: Role of a Prospective Device Selection Strategy Using Acurate and SAPIEN 3 as Complementary Devices in Transcatheter Aortic Valve Replacement

Presenter: Jonathan Michel

June 07, 2024

Advertisement

Can AI-Assisted Earlier AS Diagnosis Level the Disparities Playing Field?

Impact of Delays in Diagnosis and Treatment: Join the AHA TARGET AS Program!

Patient Perspectives and Shared Decision-Making in Younger Patients Requiring AS Therapy

Surgical Valve Selection in Younger Patients with AS: Mechanical, Bioprosthetic, or Ross?

The Emerging Use of TAVR in Younger Patients: Updates and Evidence Gaps

Transcatheter vs. Surgical Aortic Valve Replacement in Women: A Pooled Analysis of the RHEIA and PARTNER 3 Trials

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

What’s Going to Be Big at TCT 2024?

Pi-Cardia Receives FDA Market Clearance for ShortCut™

Balloon-Expandable TAVI Superior to SAVR in Women at 1 Year: RHEIA

Initial US Commercial TriClip Cases Offer Hope, but Reimbursement Still a Big Question

Knowns and Unknowns in Subclinical Aortic Valve Thrombosis

National Data Point to Soaring TAVI Rates in Patients Under 65

UPDATES: Pre-emptive AVR Clinical Trials for Moderate and Severe AS

There Is Growing Evidence to Support Earlier AS Treatment: Guidelines and Clinical Practice Are Lagging Behind!

Access Disparities Affecting Appropriate AS Therapy

Impact of Delays in Diagnosis and Treatment: Introducing the TARGET AS Program

Thoughts on Therapy Sequencing in Younger Patients With AS and Long Life Expectancy

Patient Interview: Understanding the Impact of Patient Preferences and Other Determinants of VHD Therapy Choices

Partner Valves: Role of a Prospective Device Selection Strategy Using Acurate and SAPIEN 3 as Complementary Devices in Transcatheter Aortic Valve Replacement

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content